Previous Close | 12.26 |
Open | 12.39 |
Bid | 0.00 x 1100 |
Ask | 0.00 x 1000 |
Day's Range | 11.94 - 12.83 |
52 Week Range | 1.48 - 14.62 |
Volume | 516,974 |
Avg. Volume | 1,126,216 |
Market Cap | 557.082M |
Beta (5Y Monthly) | 1.62 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.26 |
Earnings Date | Nov 05, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 25.27 |
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will present at the 10th Annual SVB Leerink Global Healthcare Conference at 3:40 p.m. ET Friday, February 26, 2021.
A look at the shareholders of Aldeyra Therapeutics, Inc. ( NASDAQ:ALDX ) can tell us which group is most powerful...
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced the finalization of the design of the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease. Consistent with previously announced results from the run-in cohort of TRANQUILITY, ocular redness over 90 minutes in a dry eye chamber will be the primary endpoint. Approximately 150 dry eye disease patients are expected to be enrolled per arm. The TRANQUILITY protocol will utilize the two-day dosing paradigm, dry eye challenge design, and enrollment criteria of the run-in cohort.